Bruker (NASDAQ:BRKR) Rating Increased to Strong-Buy at Zacks Research

Bruker (NASDAQ:BRKR) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other equities analysts have also recently weighed in on the stock. Citigroup lowered their price objective on shares of Bruker from $60.00 to $53.00 and set a “neutral” rating for the company in a research report on Wednesday. Stifel Nicolaus set a $50.00 price target on Bruker in a research note on Wednesday. JPMorgan Chase & Co. raised their price target on Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Finally, Leerink Partners lifted their target price on Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $56.64.

Bruker Stock Up 4.3%

Shares of BRKR opened at $52.47 on Tuesday. The company’s 50-day moving average price is $58.67 and its 200 day moving average price is $46.73. Bruker has a 12-month low of $28.53 and a 12-month high of $65.30. The company has a current ratio of 1.85, a quick ratio of 0.72 and a debt-to-equity ratio of 0.76. The firm has a market cap of $7.99 billion, a P/E ratio of -74.96, a price-to-earnings-growth ratio of 1.61 and a beta of 1.28.

Bruker (NASDAQ:BRKR) last announced its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. During the same quarter last year, the firm posted $0.32 earnings per share. Bruker’s revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts forecast that Bruker will post 2.12 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Los Angeles Capital Management LLC acquired a new position in Bruker in the fourth quarter valued at approximately $26,000. Parallel Advisors LLC raised its holdings in Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares in the last quarter. Allworth Financial LP lifted its position in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after buying an additional 257 shares during the last quarter. Essential Partners LLC acquired a new position in shares of Bruker in the 1st quarter valued at $36,000. Finally, FNY Investment Advisers LLC acquired a new position in shares of Bruker in the 2nd quarter valued at $60,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.